Special Issues

Signaling Pathway Crosstalk in Malignant Tumors: Molecular Targets and Combinatorial Therapeutics

Submission Deadline: 30 December 2024 View: 7 Submit to Special Issue

Guest Editors

Fu Wang, Xi’an Jiaotong University , China. E-mail: wangfu@xjtu.edu.cn

Lei Zhu, Emory University School of Medicine, USA. Email: lei.zhu@emory.edu

Jingang Huang, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, China. Email: huangjg35@mail.sysu.edu.cn


Due to its high mortality and recurrence, malignant tumors remain the most concerned health problem of people all over the world. Liver, gastric, breast, colon and lung cancers are the top five malignant tumors in terms of mortality and morbidity. Molecular changes in cancer genes and related signaling pathways are used to provide new information for precise cancer treatment. Multiple signaling pathways, such as Janus kinase/signal transducers and activators of transcription (JAK-STAT), nuclear factor kappa B (NF-kB), mitogen-activated protein kinase (MAPK), cGAS/STING , and toll-like receptor (TLR) pathways, have been identified as pivotal regulators of the initiation and resolution of cancer progression. These pathways are widely concerned and crosstalked in the processes of solid tumors.   


Small molecule inhibitors and monoclonal antibodies against cancer related signaling pathways play an important role in the successful treatment of some malignancies. These drugs inhibit the signal pathways leading to cell growth arrest and apoptosis, and bind to external receptors that mediate antibody dependent cytotoxicity (ADCC). However, the inherent limitations, such as drug toxicity, and the acquisition of new or acquired drug resistance mechanisms, will still lead to treatment failure.


Therefore, in order to provide a new level of understanding of the molecular complexity underpinning resistance to cancer therapies, this special issue aims to explore the underlying mechanism of the molecules involved in the alterations of signaling pathways, further develop preferable combination therapies approach over monotherapy for cancer treatments. We welcome submissions of original research and review articles. We hope this special issue would provide novel therapeutic developments that may complement drug delivery and significantly benefit clinical response and outcomes of cancer patients.


malignant tumors; signaling pathway; molecular targets; combinatorial treatments

Published Papers

Share Link